TY  - JOUR
AU  - Yardley, D A
AU  - Coleman, R
AU  - Conte, P
AU  - Cortes, J
AU  - Brufsky, A
AU  - Shtivelband, M
AU  - Young, R
AU  - Bengala, C
AU  - Ali, H
AU  - Eakel, J
AU  - Schneeweiss, A
AU  - de la Cruz-Merino, L
AU  - Wilks, S
AU  - O'Shaughnessy, J
AU  - Glück, S
AU  - Li, H
AU  - Miller, J
AU  - Barton, D
AU  - Harbeck, N
AU  - tnAcity investigators
PY  - 2018
DO  - 10.1093/annonc/mdy201
UR  - http://hdl.handle.net/10668/12560
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Albumins
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Chemotherapy, Adjuvant
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Mastectomy
KW  - Middle Aged
KW  - Paclitaxel
KW  - Progression-Free Survival
KW  - Triple Negative Breast Neoplasms
KW  - Gemcitabine
TI  - nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
TY  - research article
VL  - 29
ER  -